The development of safe and effective treatments for Alzheimer’s disease and dementia requires collaboration across discovery research, translational science and clinical investigation. This session examines therapeutic targets, drug development, repurposed medicines, clinical trial design and emerging treatment strategies. It also considers challenges related to patient selection, outcome measurement, safety, accessibility and long-term treatment effectiveness.
Abstract Scope and Participation
Submissions may include preclinical studies, pharmaceutical research, clinical trial results, trial protocols, drug-delivery systems, biologic treatments, immunotherapies, regenerative approaches and combination therapies. Pharmacologists, neuroscientists, clinicians, trial investigators, pharmaceutical professionals, regulatory specialists, statisticians, patient representatives and students are encouraged to contribute research and perspectives across all stages of therapeutic development.
Nazneen N Dewji
Cenna Biosciences Inc, United States
Jacqueline London
Paris Diderot University, France
Jacqueline Tuppen
Cogs Club, United KingdomSubmit your abstract Today
Title : Neuroimaging-based evaluation of scalp acupuncture for neural repair and reorganization in children with cerebral palsy
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Make a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Health care professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Somali Red Crescent Society, Somalia